We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 844

2018 Year-End U.S. Legal & Regulatory Developments
  • Paul Weiss
  • USA, United Kingdom, European Union
  • January 14 2019

The following is our summary of significant U.S. legal and regulatory developments during 2018 of interest to Canadian companies and their advisors


HFN Technology & Regulation Client Update
  • Herzog Fox & Neeman
  • USA, Netherlands, United Kingdom, European Union, France
  • December 31 2018

We are pleased to present the latest edition of our monthly Technology & Regulation Client Update, which includes a variety of key regulatory, legal


Pathways to Approval: Recent Developments in EU Pharma and Medical Device Regulation
  • McDermott Will & Emery
  • USA, European Union
  • December 26 2018

The contrast between the United States and European Union is no more apparent than when we consider the approach to centralized


How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA, European Union
  • October 29 2018

As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs are set to enter the U.S


USPTO director talks trademark clutter, Uber declares itself a verb, and beware sketchy Chinese licenses: news round-up
  • World Trademark Review
  • USA, Australia, Thailand, Uruguay, Bulgaria, China, Ecuador, European Union, Global
  • September 25 2018

Every Tuesday and Friday, World Trademark Review presents a round-up of news, developments and insights from across the trademark sphere. In our


FDA Statement Regarding Quality Assurance Efforts for Foreign Drug Manufacturing Facilities
  • Knobbe Martens
  • USA, European Union
  • September 19 2018

On September 5, 2018, the Food and Drug Administration (FDA) published a press release highlighting recent actions taken to ensure that


How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA, European Union
  • August 2 2018

As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs are set to enter the U.S


Pharmaceuticals and Brexit: Keeping the industry healthy
  • Linklaters LLP
  • United Kingdom, European Union
  • June 19 2018

It is estimated that each month 37 million packs of medicines are supplied from European countries to the UK with 45 million heading in the other


Life Sciences International Review Q2 2018
  • Morgan Lewis
  • USA, United Kingdom, European Union, France
  • June 6 2018

The most-significant recent development is the entry into force on 25 May of the EU General Data Protection Regulation. This new legislation will have


How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA, European Union
  • May 1 2018

As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs are set to enter the U.S